The study investigated patients using Orthofix’s SpinalStim bone growth therapy device experienced less pain as well as increased function and quality of life, according to a Dec. 21 news release from Orthofix.
Conducted at 10 centers in the U.S., the study included a total of 142 patients with one or more risk factors for pseudarthrosis. The patients used SpinalStim for six months after the procedure and over 82 percent experienced a successful fusion.
The study was published in the International Journal of Spine Surgery, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
